Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BOLT
Upturn stock ratingUpturn stock rating

Bolt Biotherapeutics (BOLT)

Upturn stock ratingUpturn stock rating
$5.77
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: BOLT (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

4 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $40

1 Year Target Price $40

Analysts Price Target For last 52 week
$40Target price
Low$5.2
Current$5.77
high$15.6

Analysis of Past Performance

Type Stock
Historic Profit -42.55%
Avg. Invested days 17
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 10.75M USD
Price to earnings Ratio -
1Y Target Price 40
Price to earnings Ratio -
1Y Target Price 40
Volume (30-day avg) 4
Beta 0.91
52 Weeks Range 5.20 - 15.60
Updated Date 06/30/2025
52 Weeks Range 5.20 - 15.60
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -33.2

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -991.41%

Management Effectiveness

Return on Assets (TTM) -34.57%
Return on Equity (TTM) -83.92%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -3374720
Price to Sales(TTM) 2.96
Enterprise Value -3374720
Price to Sales(TTM) 2.96
Enterprise Value to Revenue 64.2
Enterprise Value to EBITDA 0.93
Shares Outstanding 1916980
Shares Floating 1438199
Shares Outstanding 1916980
Shares Floating 1438199
Percent Insiders 2.26
Percent Institutions 47.25

Analyst Ratings

Rating 2
Target Price 40
Buy -
Strong Buy 1
Buy -
Strong Buy 1
Hold 3
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Bolt Biotherapeutics

stock logo

Company Overview

overview logo History and Background

Bolt Biotherapeutics was founded in 2015. It focuses on developing immuno-oncology therapies to harness the power of the immune system to fight cancer. The company has advanced its Boltbodyu2122 Immune-Stimulating Antibody Conjugate (ISAC) platform, designed to redirect the immune system to eliminate tumor cells.

business area logo Core Business Areas

  • Boltbodyu2122 ISAC Platform Development: Development of novel immunotherapies based on the Boltbodyu2122 ISAC platform, which conjugates antibodies targeting tumor-associated antigens with immune-stimulating agents.
  • Clinical Trials and Research: Conducting preclinical research and clinical trials to evaluate the safety and efficacy of their ISAC product candidates in various cancer types.

leadership logo Leadership and Structure

Dr. Elizabeth Tallett serves as the Chair of the Board of Directors. The executive team is led by Randall C. Schatzman, Ph.D., President and Chief Executive Officer. The company structure includes research, development, clinical operations, and business development departments.

Top Products and Market Share

overview logo Key Offerings

  • BDTX-1535: BDTX-1535 is Bolt's lead Boltbody ISAC candidate targeting solid tumors expressing HER2. It is currently in Phase 1/2 clinical trials. Competitors in the HER2-targeted therapy space include Roche (Herceptin, Perjeta, Kadcyla) and AstraZeneca/Daiichi Sankyo (Enhertu). Market share data for this specific candidate is not publicly available as it is still in clinical development.
  • BDT6001: BDT6001 is targeting solid tumors expressing EGFR. It is currently in Phase 1/2 clinical trials. Competitors in the EGFR-targeted therapy space include Eli Lilly(Erbitux) and AstraZeneca(Tagrisso). Market share data for this specific candidate is not publicly available as it is still in clinical development.

Market Dynamics

industry overview logo Industry Overview

The immuno-oncology market is experiencing significant growth, driven by advances in understanding the interaction between the immune system and cancer. The field includes checkpoint inhibitors, CAR-T cell therapy, and antibody-drug conjugates. Competition is intense, with numerous companies developing novel immunotherapies.

Positioning

Bolt Biotherapeutics is positioned in the immuno-oncology market with its proprietary Boltbodyu2122 ISAC platform. Their competitive advantage lies in their approach to redirecting the immune system specifically to tumor cells, potentially minimizing off-target effects.

Total Addressable Market (TAM)

The immuno-oncology market is expected to reach hundreds of billions of dollars in the coming years. Bolt is positioned to address a segment of this TAM by developing therapies for solid tumors. Exact TAM is dependent on the success of their clinical trials and the specific indications they pursue.

Upturn SWOT Analysis

Strengths

  • Proprietary Boltbodyu2122 ISAC platform technology
  • Strong scientific team and experienced leadership
  • Potential for targeted immune activation and reduced toxicity
  • Focus on addressing unmet needs in solid tumors

Weaknesses

  • Early-stage clinical development (high risk)
  • Reliance on single technology platform
  • Limited financial resources compared to larger competitors
  • Dependence on collaborations and partnerships

Opportunities

  • Expanding pipeline with new Boltbodyu2122 ISAC candidates
  • Partnering with larger pharmaceutical companies for development and commercialization
  • Exploring new indications for existing product candidates
  • Advancements in tumor microenvironment research

Threats

  • Clinical trial failures
  • Competition from established immuno-oncology therapies
  • Regulatory hurdles and delays
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • LLY
  • AZN
  • BMY
  • MRK
  • PFE
  • NVS

Competitive Landscape

Bolt Biotherapeutics competes in the broader immuno-oncology space. Its advantage lies in its Boltbody ISAC platform, but it faces competition from established players with approved therapies and larger financial resources.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by advancing preclinical programs into clinical trials.

Future Projections: Future growth is dependent on clinical trial outcomes and potential partnerships.

Recent Initiatives: Recent initiatives include advancing BDTX-1535 and BDT6001 to Phase 1/2 clinical trials, and forming strategic partnerships.

Summary

Bolt Biotherapeutics is an early-stage immuno-oncology company with a promising Boltbody ISAC platform. The company is heavily reliant on successful clinical trial outcomes. Potential partnerships and further pipeline development will be crucial for future growth. Competition in the immuno-oncology market is intense and the company's success hinges on its ability to differentiate its approach.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Industry Reports
  • Analyst Reports

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Market share data is estimated and may not be precise. Clinical trial outcomes are uncertain, and the company's future performance is subject to various risks.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Bolt Biotherapeutics

Exchange NASDAQ
Headquaters Redwood City, CA, United States
IPO Launch date 2021-02-05
CEO, CFO, President, Secretary & Director Mr. William P. Quinn
Sector Healthcare
Industry Biotechnology
Full time employees 52
Full time employees 52

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc.; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.